Actavis to keep selling Alzheimer's drug in U.S. for 60 days
September 24, 2014 at 17:05 PM EDT
NEW YORK, Sept 24 (Reuters) - Actavis Plc has reached an agreement with New York's attorney general to keep selling a top Alzheimer's drug for 60 days so U.S. patients will not be forced to switch to a newer, more expensive form of the drug with additional patent protection.
